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Abstract 
We hypothesized that Nandrolone (ND)-abuse induces cardiac hypertrophy, increases myocardial 
susceptibility to ischemia/reperfusion (I/R) injury, and reduces responsiveness to postconditioning 
(PostC) cardioprotection. Wistar-rats were ND-treated for 2-weeks (short_ND) or 10-weeks 
(long_ND). Vehicle-treated rats served as controls. Hearts were retrogradely perfused and left 
ventricular pressure (LVP) was measured before and after 30-min global ischemia. In subgroups 
of hearts, to induce cardioprotection a PostC protocol (five cycles of 10-s reperfusion and 10-s 
ischemia) was performed. β-adrenoreceptors, kinases (Akt and GSk-3β) and phosphatases (PP2A 
sub A and PP2A sub B) were examined by Western blot before and after ischemia. After 120-min 
reperfusion infarct-size was measured. Short_ND slightly increased cardiac/body weight ratio, but 
did not affect cardiac baseline nor post-ischemic contractile function or infarct-size when 
compared to vehicle hearts. However, PostC limited cardiac dysfunction much more in short_ND 
hearts than other groups. Although cardiac/body weight ratio markedly increased after long_ND, 
baseline LVP was not affected. Yet, post-ischemic contracture and infarct-size were exacerbated 
and PostC was unable to reduce infarct-size and ventricular dysfunction. While short_ND 
increased phosphatases, non-phosphorylated and phosphorylated Akt, long_ND reduced 
phosphatase-expression and Akt-phosphorylation. Both short_ND and long_ND had no effect on 
the GSK-3β-phosphorylation but increased the expression of β2-adrenoreceptors. In reperfusion, 
PostC increased Akt-phosphorylation regardless of protective effects, but reduced phosphatase-
expression in protected hearts only. In conclusion: short_ND improves post-ischemic myocardial 
performance in postconditioned hearts. However, long_ND increases myocardial susceptibility to 
I/R injury and abolishes cardioprotection by PostC. This increased susceptibility might be related 
to steroid-induced hypertrophy and/or to altered enzyme expression/phosphorylation. 
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 Introduction 
 Ischemia/reperfusion (I/R) of the heart causes cell injury and death, which result in cardiac 
contractile dysfunction (myocardial contracture and stunning) and infarction. Clearly 
postconditioning (PostC, i.e., repetitive cycles of reperfusion and coronary occlusion following an 
ischemic insult) causes massive salvage of the myocardium exposed to I/R. The extension of 
protection by PostC and the transduction pathways involved in PostC are similar to those of 
ischemic preconditioning (IP) [3,10,21,34,62,65]. In particular the protective cascades may 
involve post-translational modifications mainly mediated by the activity of several kinases 
[3,10,12,21,22,34] and phosphatases [7,2134,62] in reperfusion. Several signaling pathways of 
cardioprotection converge to increase the threshold for mitochondrial permeability transition pore 
opening [3,4,11,23,24,34,43]. However, the details of the signal transduction of postconditioning 
remain unclear [21-23,55]. 
 There is a growing body of evidence indicating an increasing prevalence of the abuse of 
anabolic-androgenic steroid (AAS) in both non-athletes and athletes. Likewise, the number of 
people abusing AAS and being admitted to hospital for infarction is increasing. These patients are 
displaying angiographically normal arteries [1,35]. Nandrolone (ND), an AAS strongly associated 
with detrimental cardiovascular effects including sudden cardiac death, is commonly abused by 
humans [1,35]. When administered chronically to rats, ND has been associated with accelerated 
development of hypertension in developing spontaneously hypertensive rats (SHR) [61] and with 
left ventricular hypertrophy [60,61] in sedentary rats. More recently left ventricular hypertrophy 
and increased myocardial susceptibility to I/R injury have also been shown in isolated hearts 
prepared from rats treated chronically with ND [13]. However, we recently have shown that sub-
chronic treatment with ND for 14 days does not induce an evident left ventricular hypertrophy 
and, paradoxically, improves PostC cardioprotection [36]. Since cardiac hypertrophy is 
accompanied with alteration of function and expression of several proliferative modulators, such 
as kinases and phosphatates [53], many of which are involved in cardioprotection [10,21,22,34], 
we wondered whether treatment with ND, which induces cardiac hypertrophy, would alter the 
expression/activity of these enzymes and then would suppress the protective response to a PostC 
protocol. 
 Therefore, we hypothesized that chronic ND-abuse would increase myocardial 
susceptibility to ischemia/reperfusion (I/R) injury, and would reduce responsiveness to 
cardioprotective maneuvers only when myocardial hypertrophy is evident. Moreover, to our 
knowledge, thus far no investigation has been performed to study the effect of chronic ND on 
both infarct size and post-ischemic mechanical recovery after I/R with and without PostC in the 
same hearts. Importantly, no studies have compared the effects of sub-chronic and chronic ND in 
terms of development of hypertrophy and alteration of proliferative modulators, and in terms of 
alterations of responsiveness to I/R or cardioprotective maneuvers. 
 Thus, this study was performed in isolated rat hearts, in which infarct size and post-
ischemic cardiac function were studied in response to I/R and PostC. Hearts were harvested from 
rats, which had undergone two ND treatments with different duration (14 days or 10 weeks). At 
the end of ND-treatment (two or ten weeks) the activation/inactivation (phosphorylated/total 
ratio) of kinases (Akt and GSk-3β) and expression of phosphatases (PP2A sub A and PP2A sub 
B) were analyzed and compared with vehicle-treated hearts. Phosphorylation of kinases and levels 
of phosphatases were also analyzed during reperfusion.  
 
 
Materials and Methods 
 The methods are similar to those previously described [36,37]. These studies were carried 
out in accordance with the Guide for the Care and Use of Laboratory Animals (U.S. National 
Institutes of Health) and with Italian law (DL-116, Jan. 27, 1992) and approved by the ethical 
committee of the University of Turin. 
All animals were housed in our animal facilities at the age of 3 months, weighed and 
randomly assigned to one of the following three groups. 
 The 1st group: 3 months old male rats (Chronic, long_ND, n= 14) were treated twice a 
week for 10 weeks with an i.m. injection of 0.5 ml/kg of peanut oil solution containing 5 mg/kg of 
ND [60]. 
 The 2nd group: 3 months old male rats (Sub-Chronic, short_ND, n= 14) were housed in our 
animal facility until the animals were 5 months old, then was treated daily for 2 weeks with an 
i.m. injection of 0.5 ml/kg of peanut oil solution containing 15 mg/kg of ND [30,36,37]. 
 The 3th group: 3 months old male rats (vehicle, n= 12) were treated twice a week for 10 
weeks with an i.m. injection of 0.5 ml/kg of peanut oil and served as control group. A group of 
short_vehicle controls was not considered because we had observed that 14 days of 0.5 
ml/(kg/day) peanut-oil was ineffective in changing the studied parameters (body weight, organ 
weights, including the heart weight, heart performance and infarct size following I/R) when 
compared to untreated animals (unpublished observations). In particular, in our previous study 
[37] the infarct size and post-ischemic mechanical function of the short vehicle group were 
similar to those observed several times in untreated animals in our laboratory [38,40,44-46]. 
Animal Sacrifice and Isolated Heart Perfusion 
 Methods for isolated rat hearts were similar to those previously described [38,40,42,44-
46]. In brief, at the end of treatment (animal age= 5.5 months) each animal was weighed and 
treated with heparin (800 U/100 g b.w., i.m.). Then, 10-min afterwards, animals were sacrificed; 
the heart was rapidly excised, placed in ice-cold buffer solution and weighed. Several organs 
(liver, kidney, prostate, spleen, pituitary and adrenal gland) were also harvested and weighed. 
 Isolated hearts were retrogradely perfused with oxygenated Krebs–Henseleit buffer (127 
mM NaCl, 17.7 mM NaHCO3, 5.1 mM KCl, 1.5 mM CaCl2, 1.26 mM MgCl2, 11 mM D-glucose 
and gassed with 95% O2 and 5% CO2) at constant flow (9±1 ml/min/g), paced at 280 bpm and 
kept in a temperature-controlled chamber (37°C) [38,40,42,44-46]. Coronary perfusion pressure 
and left ventricular pressure were monitored to assess the preparation conditions. During the 
stabilization period the flow was titrated to reach a coronary perfusion pressure (CPP) of about 85 
mmHg. Left ventricular pressure (LVP) was recorded by a polyvinyl chloride balloon placed in 
the left ventricle via the mitral valve and connected to an electromanometer (Monitoring Kit mk 
5-02 DTBNVF, Abbott, Milan, Italy). The balloon was saline-filled to achieve an end-diastolic 
LVP (LVEDP) of 5 mmHg. LVP was analyzed offline with Lab View software (National 
Instruments), which allowed the determination of LVEDP, as well as the developed LVP (dLVP) 
and the maximum rate of increase (dP/dtmax) and decrease (dP/dtmin) of systolic LVP. While 
LVEDP and dP/dtmin are used as indices of diastolic function, dLVP and dP/dtmax are considered 
indices of contractile state. In particular LVEDP is used to monitor contracture, which can be 
defined as an increase in intrachamber pressure of 4 mmHg above pre-ischemic (baseline) 
LVEDP values [33]. The cardiac/body weight ratio was used as an index of cardiac hypertrophy 
[13,60]. 
Experimental protocols 
 After a stabilization period (40 min), hearts of the three groups (long_ND, short_ND, and 
vehicle) were subjected to a specific protocol, which included a period of 30-min of global no-
flow ischemia and a subsequent period of 120-min of reperfusion (I/R). In subgroups, 
immediately after the 30-min of ischemia, the hearts underwent a protocol of PostC. This 
consisted of five cycles of 10-s reperfusion and 10-s ischemia at the beginning of reperfusion 
[38,40,44-46]. 
 Therefore the following six subgroups were studied (three subgroups of hearts underwent 
I/R only and three received PostC immediately after 30-min ischemia): 
1) vehicle+I/R (n= 6); 2) vehicle+PostC (n= 6), which served as controls; 
3) short_ND+I/R (n= 7); 4) short_ND+PostC (n= 7); 
5) long_ND+I/R (n= 7); 6) long_ND+PostC (n= 7). 
Western blotting analysis  
 To investigate the level of phosphatases (PP2A sub A and PP2A sub B) and the ratio of 
phosphorylated/total form of kinases (Akt and GSK-3β) after ischemia, in the six treatment 
groups above reported, samples of left ventricles were collected and freeze-clamped for Western 
blotting at the 60th min of reperfusion. To study the levels of these enzymes in the baseline 
conditions additional vehicle, short_ND and long_ND hearts (n=4 for each condition) were 
examined. These hearts were mounted on the Langendorff perfusion apparatus, perfused for the 
stabilization time and then the left ventricle was collected. Samples were homogenized on ice in 
RIPA Lysis buffer (Santa Cruz Biotechnology), using a polytron tissue grinder. The homogenate 
was centrifuged at 4°C for 30-min at 13,000 g. Protein level was determined by Bradford's 
method [8]. About 50-100 µg of protein extracts were separated by SDS-PAGE on 10% 
acrylamide gels (for Akt, p-Akt, GSK-3β; p- GSK-3β; PP2A sub A; PP2A sub B) and transferred 
to PVDF membranes (GE-Healthcare). These were then incubated overnight at 4°C with the 
following primary antibodies: anti-PP2A sub A, anti-PP2A sub B, anti-Akt, anti-phospho-
(Ser473)-Akt, anti-GSK-3β, anti-phospho-(Ser-9)-GSK-3β (Cell Signalling). To confirm equal 
protein loading, membranes were incubated with an anti-α-actin antibody (Sigma). 
Immunoblotted proteins were visualized by Immuno-Star HRP Substrate Kit (BioRad) and 
quantified by Kodak Image Station 440CF. Image analyses were performed with Kodak 1D 3.5 
software [41,43]. 
 Positive control: since ND treatment is accompanied by alteration of the expression of 
adrenoreceptors (AR) [36,37 and references therein], rat left ventricle lysates were also 
immunoprecipitated and immunoblotted with anti-β1- and anti-β2-AR polyclonal antibodies 
(Santa Cruz Biotech) according to the method previously reported [36,37]. 
Assessment of myocardial injury 
 At the end of the experiment, i.e., directly after 120-min reperfusion, each heart was 
rapidly removed from the perfusion apparatus and the left ventricle (LV) was dissected into 2–3 
mm circumferential slices. Following 15-min of incubation at 37°C in 0.1% solution of nitro-
blue-tetrazolium in phosphate buffer [38,40,42,44-46], unstained necrotic tissue was carefully 
separated from stained viable tissue by an independent observer who was not aware of the nature 
of the intervention. The weights of the necrotic and non-necrotic tissues were then determined and 
the necrotic mass was expressed as a percentage of total left ventricular mass, which is considered 
the risk area. 
Chemicals 
 We used a commercially available ND solution of 50 mg/ml (Deca-Durabolin, Organon, 
Italy). All other chemicals were purchased from Sigma (USA) if not otherwise specified. 
Statistical analysis 
 All data are means±S.E.M. One-way ANOVA and One-way ANOVA for multiple 
measures (post test: Newman-Keuls Multiple Comparison Test) were used for the analysis of 
infarct size and LVP data, respectively. A p value < 0.05 was considered significant. 
 
 Results 
Effect of ND pre- treatment over organs and body weight (Table 1) 
At three months old, when animals were assigned to the different groups, they all had 
similar body weights, while at the end of treatment, just before the sacrifice (i.e. at 5.5 months of 
age), the body weights of long_ND treated animals resulted significantly (p< 0.01, for both) less 
than those of vehicle-treated animals and short_ND treated animals (vehicle vs short_ND p= NS). 
The inhibition of weight gain by ND has been associated to ND-induced modulation of 
proopiomelanocortin (POMC) expression and alteration of the central melanocortin system [30]. 
At the end of treatment, cardiac weight increased from 1.42±0.04 in vehicle group, to 1.61±0.05 
in short_ND and to 1.65±0.03 g in long_ND group. Moreover, cardiac to body weight ratio 
increased from 0.31±0.001 in vehicles to 0.36±0.009 (+15%, p< 0.05) in short_ND, and to 
0.41±0.09 g/100g bw (+31%, p<0.001) in long_ND animals (short_ND vs long_ND p<0.05). 
Therefore, there was evidence of a slight cardiac hypertrophy in short_ND treated animals and a 
marked hypertrophy in animals treated with ND for long period, compared with vehicles animals. 
The kidney and prostate of short_ND and long_ND treated animals were found to be 
heavier than those of untreated animals. While the prostate weight variations are not consistent in 
the various protocols, the kidney weight increase is typical in rats ND-treated with similar 
schedules and doses [19,30,36,61]. 
Effect of ND pre-treatment over baseline hemodynamic parameters 
In baseline conditions hearts of the three groups had similar cardiac performance, i.e. no 
significant differences were observed in hemodynamic parameters among groups (Table 1). 
Effect of I/R and PostC on cardiac function and injury in ND-pre-treated and vehicle-pre-
treated animals 
 Ischemia and the subsequent reperfusion caused diastolic dysfunction characterized by an 
increase in LVEDP and a reduction in dP/dt
 min, and a systolic dysfunction evidenced by a 
decrease in dP/dtmax and in developed LVP. These parameters were differently affected by both 
I/R and PostC in the different experimental groups. 
 Post-ischemic Diastolic function (Fig. 1) 
 Diastolic dysfunction was analyzed by variations of LVEDP (Fig. 1, panels A and B) and 
dP/dtmin (Fig. 1, panels C and D) during reperfusion, in I/R (panels A and C) and PostC (panels B 
and D). LVEDP analysis revealed that the time-course of contracture was different between 
long_ND+I/R from one side, and short_ND+I/R and vehicle+I/R hearts on the other side (Fig. 
1A). In particular, LVEDP was higher in hearts of long_ND+I/R compared to both vehicle+I/R 
and short_ND+I/R subgroups; in fact at the end of reperfusion the values were 78±24 vs 
48±11and 48±15 mmHg, respectively (p<0.05, long_ND+I/R vs both vehicle+I/R and 
short_ND+I/R). Differences were not significant among I/R groups in terms of lusitropic effect as 
indicated by dP/dtmin (Fig. 1C). 
Postconditioning confirmed its cardioprotective effect in the vehicle+PostC hearts, in fact 
in this subgroup at the end of reperfusion the LVEDP was significantly (p<0.05) reduced to 29±7 
mmHg. PostC maneuvers also reduced LVEDP to 35±9 mmHg in the short_ND treated hearts 
(p<0.05 vs short_ND+I/R; p=NS vs Vehicle+PostC). However, in the long_ND+PostC the 
LVEDP was 80±12 mmHg at the end of reperfusion (Fig. 1B), i.e. not different from that 
observed in long_ND+I/R (Fig. 1A). 
The dP/dtmin variations present a similar trend: only the vehicle+PostC and 
short_ND+PostC show a significant improvement of dP/dtmin recovery by PostC with respect to 
the correspondent I/R protocols (p<0.05 vs I/R; Fig. 1, panels C and D).  
Post-ischemic Systolic function (Fig. 2) 
Post-ischemic systolic dysfunction was analyzed by dLVP (Fig. 2, panels A and B) and 
dP/dtmax reduction in reperfusion (Fig. 2, panels C and D). No differences of these two parameters 
were seen among groups during post-ischemic periods in hearts subjected to I/R only (Fig. 2 
panels A and C). 
However, post-ischemic systolic function was slightly improved by postconditioning in 
vehicle subgroup, and markedly improved in short_ND+PostC hearts. In particular, 
short_ND+PostC showed higher post-ischemic dLVP and dP/dtmax with respect to hearts of both 
Vehicle- and long_ND treated groups (Fig 2, panels B and D). In fact, in the short_ND+PostC 
hearts, at the end of reperfusion, the recovery of dLVP and dP/dtmax were above 70% of baseline 
levels. The worsening of cardiac performance in the long_ND+PostC was similar to that of 
long_ND+I/R hearts, i.e. PostC was not protective (Fig. 2, panels C and D). 
 Infarct size (Fig.3) 
 Total infarct size, expressed as a percentage of left ventricular mass was 61±5% of risk 
area in hearts of vehicle pre-treated animals. Short_ND pre-treatment did not significantly affect 
infarct size of hearts subjected to I/R, infarct size being 53±10% of the risk area. However, 
long_ND pretreatment increased infarct size of hearts subjected to I/R, infarct size being 81±5% 
of  the risk area (p< 0.05 vs vehicle groups). 
 The postconditioning maneuvers induced a significant reduction of infarct size both in 
hearts of vehicle pre-treated animals and in short_ND treated, infarct size being 35±7 and 30±3% 
(p<0.05 with respect to correspondent I/R; p=NS vs each other). However, in the 
long_ND+PostC, PostC was unable to reduce infarct size; in fact it was 72±5% of the risk area. 
Western blotting analysis 
The immunoprecipitated and immunoblotted assay, as seen in Fig. 4, confirmed the 
overexpression of β2-ARs during both short and long treatment with ND, as previously shown for 
short treatment only [36,37]. No changes in β1-AR expression were observed either in short or 
long treatment (data not shown) as previously reported for short treatment only [36,37]. 
 In Fig. 5 the ratios of phosphorylated/total kinases (Akt and GSK-3β) in baseline 
conditions are reported. After sub-chronic treatment (Short_ND) no appreciable changes in Akt 
and GSK-3β ratios were observed. However, after chronic treatment (Long_ND) only Akt ratio 
was significantly reduced. Of note, in Short_ND hearts the maintained Akt ratio is due to an 
increase of both the total and phosphorylated forms. However, in Long_ND hearts the marked 
Akt ratio reduction is due to both an increase in total Akt and the almost complete absence of 
phosphorylation. Apparently there is also a slight tendency of total GSK-3β increase in Long_ND 
hearts. 
In Fig. 6 the ratios of phosphorylated/total kinases (Akt and GSK-3β) in reperfusion in 
both I/R and PostC subgroups are reported. As can be seen, in I/R subgroup Akt ratio shows a 
trend similar to that observed in baseline conditions in response to treatments, i.e., with a 
significant reduction of this ratio in Long_ND animals only. However, in PostC the 
phosphorylated/total ratios are higher than in the I/R hearts. On the other hand GSK-3β ratios 
were higher in I/R and PostC than those observed in baseline conditions, but PostC induced no 
appreciable changes in these ratios in the three treatment groups. 
In Fig. 7 the expression of phosphatases (PP2A sub A and PP2A sub B) in baseline 
conditions is reported. The expression of both subunits increased after Short_ND, and decreased 
after Long_ND, the subunits being PP2A sub A below and sub B at Vehicle levels in the 
Long_ND group. 
In Fig. 8 the expression of phosphatases (PP2A sub A and PP2A sub B) in reperfusion is 
reported. As can be seen the expression of both subunits shows similar trends in reperfusion to 
those observed in baseline conditions in the three groups. Comparing I/R with PostC we observe a 
significant reduction for PP2A sub A in protected hearts (Vehicle and Short_ND) and, in 




 Here we report that sub-chronic treatment with the potentially toxic Nandrolone renders 
the postconditioned heart more resistant to ischemic injury, improving post-ischemic mechanical 
recovery. However, this protection is lost a few weeks afterwards, and I/R injury is increased, 
possibly as hypertrophic cardiomyopathy develops. Clearly the use of chronic models better 
reflects the clinical situation of compulsive abuse observed in humans AAS addicts, in which 
detrimental cardiovascular effects, including sudden cardiac death is commonly observed [36]. 
The increased protection in sub-chronic ND-treated heart and the increased susceptibility of the 
chronically ND-treated heart to I/R injury may be related to developing hypertrophy, which in an 
initial phase is characterized by preservation/potentiation of protective mechanisms; then, these 
mechanisms are exhausted and I/R injury increases. This shift from potentiation to worsening is 
reminiscent of the observed increase/reduction of the resistance to I/R injury when diabetes is 
induced by streptozotocin or alloxan administration [18]. Actually, dose- and time-dependency in 
determining detrimental vs beneficial effects has been observed for other compounds, including 
PAF [41,42] and TNFα [21,26]. 
We did not find any differences between the basal pre-ischemic function of the hearts 
from vehicle- and ND-treated animals with either treatment regimes (sub-chronic and chronic). 
This lack of effect of ND may be related to the model we used and/or to the dose of the steroid we 
choose from the literature [30,57]. In the studies where baseline mechanical function of the hearts 
was compromised, the doses of different AAS were somewhat higher [27,50]. In particular, while 
LeGros et al. [27] used isolated rat hearts in which an intra-ventricular balloon was filled to 
achieve an identical diastolic volume in the different experimental groups, we instead, filled the 
balloon to achieve the same baseline LVEDP, as is usually done in I/R studies [20,38,40,42,44-
46]. Therefore, we cannot rule out whether chronic treatment with anabolic steroids may reduce 
left ventricular compliance, as shown by LeGros et al. [27]. 
 We did, however, find that the hearts from animals that were on a chronic treatment 
program developed higher susceptibility to I/R injury and they lost the possibility to reduce 
infarct size with a well-characterized protective protocol [38,40,44-46]. The long_ND treatment 
significantly reduced the cardioprotective effect by PostC, with an increase of infarct size and 
reduction of cardiac performance. Paradoxically, the short_ND pre-treatment enhanced the 
cardioprotective effect of PostC, improving both diastolic and systolic functions during 
reperfusion. This is not associated with a further reduction of infarct size, suggesting a better 
improvement of stunning with respect to PostC in the control group. This aspect is very intriguing 
and has been attributed to the over-expression of β2 adrenergic receptors, which are involved in 
the cardioprotection induced by PostC [37]. In fact, the release of catecholamines from 
sympathetic terminal nerves and β-AR stimulation play an important role in cardioprotection 
against necrosis and/or stunning [31,47,59,64]. We previously reported that the β2-AR antagonist, 
ICI-118.551, abolishes PostC-protection both in ND- and vehicle-pretreated hearts [37]. Also 
Penson et al. [48] suggested that PostC-protection can be prevented by the same β2-AR antagonist 
in isolated rat hearts. 
 β2-AR over-expression may be taken as an index of ND treatment [36,37]. Yet this over-
expression may represent a first modification that will lead to cardiac hypertrophy, as is the case 
for transgenic mice that overexpress β2-ARs [29]. These receptors are even more upregulated in 
the long_ND hearts, where I/R injury are exacerbated and cardioprotection by PostC lost. In fact, 
in our model hypertrophy develops progressively during treatment with ND, arriving at 
borderline levels after two weeks and very evident after ten weeks of treatment. Actually, with the 
two week regime treatment, the increase of heart/body weight ratio was not significant in our 
previous study [37] and it is slightly significant in the present study. Nevertheless, only when 
hypertrophy is evident cardioprotection is lost. The gain or loss of protection may be related to 
discrete alterations in intracellular enzymes and pathways (see below). 
 Our data confirm results from a recent study showing that chronic ND treatment induced 
cardiac hypertrophy and increased the susceptibility of hearts to I/R injury [13] and are in 
agreement with a more recent study showing that a 8 week treatment with ND impairs exercise-
induced cardioprotection [9]. Data of the present study are also in line with our previous 
observation that PostC protection is impaired in hypertrophic hearts of SHR [46]. However, it is 
not clear whether hypertrophic hearts can be protected by PostC. In hearts from 2-year old mice (a 
model that displays definitive morphometric and molecular hallmarks of cardiovascular aging, 
including hypertrophy), no benefit was seen in any of the multiple PostC algorithms that were 
evaluated [52]. However, Fantinelli & Mosca [16] reported that PostC was as effective as 
preconditioning in improving the post-ischemic dysfunction of hearts isolated from SHR. Yet in 
two different models of overload myocardial hypertrophy, Zhu et al. [66] in post-ischemic 
remodeled myocardium and Li et al. [28] in transverse aortic constriction in mice reported 
preserved PostC cardioprotection. 
 A limit to the present study is that we used a single PostC protocol, but did not check 
whether or not this stimulus was submaximal in hypertrophic hearts. Our study only suggests that 
a specific PostC protocol that is ideal for normo-trophic hearts is not working in hyper-trophic 
hearts of animals after chronic treatment with ND. Therefore, we cannot rule out that protective 
PostC protocol also exists for ND-treated hypertrophic hearts. Nevertheless, we should consider 
that it is not easy to ascertain whether or not increasing or reducing the numbers and/or the 
duration of postconditioning I/R cycles would be protective [25,56]. In fact, reducing the 
“additive ischemia” (cumulative coronary re-occlusions during PostC) from 2 to 1% of index 
ischemia in aging mice fully reestablished the protection [2,5,56]. Yet, in porcine hearts an 
increase in “additive ischemia” was necessary to show effectiveness [39,55,56]. Finally, as said, 
in aging hypertrophic mouse heart no benefit was seen in any of the multiple PostC algorithms 
that were evaluated [52]. Whether infarct size reduction with PostC is, indeed, preserved in 
hypertrophic myocardium remains to be assessed in future studies. On the basis of the present 
study, we can argue that preserved PostC-induced protection is typical of moderate/initial 
hypertrophy. 
 It has been suggested that in rodent models contracture development, rather than systolic 
function, may be a more appropriate end-point to study the protective effects of cardioprotective 
maneuvers [20,45]. The present study confirms this point of view; in fact contracture 
development matches very well with infarct size in all the experimental conditions. In particular, 
a higher level of contracture is observed in hypertrophic long_ND treated hearts, which develops 
greater infarct size and looses PostC protection. 
 Heart hypertrophy and failure are associated with diminished β-adrenergic responsiveness, 
altered protein phosphatase activity, and altered protein phosphorylation [14,63]. We previously 
reported altered β-adrenergic responsiveness in short_ND treated rats [36]. Here we observe 
reduced phosphorylated/total ratio of Akt only after chronic treatment with ND. However, 
phosphatases levels (both sub A and sub B of PP2A) increased after sub-chronic ND and then 
decreased after chronic ND treatments. Whether these enzyme alterations play a causal role in 
both hypertrophy and altered responses to I/R cannot be inferred. Nevertheless, data show that the 
impact on baseline levels of kinases and phosphatases is different, depending on the duration of 
ND treatment. We can argue that after short_ND-treatment up-regulation of PP2A may represent 
a feedback regulator of the increased activation of the PI3K/Akt pathway, as revealed by 
increased Akt level and phosphorylation (Fig. 5). Yet reduced phospho-Akt and increased GSK-
3β total levels in long_ND-treatment might act as negative modulators of proliferation and 
protection. [12,58]. After ischemia/reperfusion Akt phosphorylation is particularly low in more 
vulnerable hearts (i.e., Long_ND group). However, albeit starting from different levels, the 
increase in Akt phosphorylation is observed after PostC in all groups, regardless of protective 
effects. This supports the hypothesis that Akt phosphorylation in PostC needs to reach a threshold 
to be protective or alternatively that it may be an epiphenomenon [54,55]. Moreover, GSK-3β 
ratios are not correlated to protective effects; in fact the role of GSK-3β phosphorylation in PostC 
has been questioned [32]. Finally, PostC reduces the levels of PP2A when is protective. In 
particular, in short_ND, PostC reduces both PP2A subunits. Whether these reductions are 
somehow correlated to protection and to the maintained level of Akt phosphorylation needs to be 
confirmed. Actually, this different framework in the expression/activity of enzymes in the two 
ND-treatment regimes with and without I/R and PostC deserves further studies. Nevertheless, our 
results are in line with a recent study [7] showing that other phosphatases (PTEN, MKP-3, and 
PP2C) are significantly decreased in wild-type mice by PostC protection, but are increased by 
PostC in ob/ob mice, which cannot be protected. Although we did not study the catalytic subunit 
of PP2A and did not directly measure PP2A activity, one could speculate that a reduced 
phosphatase activity could be responsible for the enhanced phosphorylation of protecting kinases 
and therefore contributes to beneficial effect of PostC. Intriguingly, alterations in phosphatase 
expression or activity limit the efficacy of both pre- and postconditioning during aging and 
cardiac hypertrophy [17,52]. 
In conclusion, sub-chronic use of high concentrations of ND, improves post-ischemic 
cardiac function in postconditioned hearts. However, chronic treatment with ND induces marked 
myocardial hypertrophy, increases cardiac susceptibility to I/R injury and abolishes the possibility 
to induce postconditioning protection. Moreover, both sub-chronic and chronic ND treatments 
increase β2-AR expression. Yet only chronic ND treatment markedly decreases the 
activity/expression of important enzymes (phosphorylated Akt and PP2A levels) involved in both 
cardiomyocyte growth and protection. It seems that maintenance of adequate PP2A expression 
and appropriate ratio of phosphorylated/total form of Akt in basal conditions are necessary to 
preserve the possibility for future PostC cardioprotection. Starting from these adequate levels a 
concomitant increase in Akt phosphorylation and a reduced level of PP2A occur with PostC 
protection in this model. Yet the increase in Akt phosphorylation is not always associated to 
cardioprotection, especially if it starts from inadequately low pre-ischemic levels and/or occurs 
without concomitant PP2A downregulation. Nevertheless, whether the observed enzyme 
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Figure legends 
Fig 1. Diastolic function. Left ventricular end diastolic pressure (LVEDP, mmHg, panel A) and 
percent variation of dp/dtmin with respect to baseline level (panel B), during the 30 min ischemia 
and 120 min reperfusion. Time 0 correspond to the beginning of reperfusion. I/R, 
Ischemia/Reperfusion; PostC, Postconditioning. † p< 0.05 vs Vehicle; * p<0.05, vs I/R. 
 
Fig 2. Systolic function. Percent variation of developed left ventricular pressure (dLVP, panel A) 
and percent variation of dp/dtmax with respect to baseline (panel B) during the 30 min ischemia 
and 120 min reperfusion. Time 0 correspond to the beginning of reperfusion. I/R, 
Ischemia/Reperfusion; PostC, Postconditioning. † p< 0.05 vs Vehicle; * p<0.05, vs I/R; ** p< 
0.01 vs I/R. 
 
Fig. 3 Infarct size (IS). The amount of necrotic tissue is expressed as percent of the left ventricle 
(LV), which is considered the risk area. I/R, Ischemia/Reperfusion; PostC, Postconditioning. 
* p<0.05, vs I/R; † p< 0.05 vs Vehicle. 
 
Fig 4. Expression of β2-Adrenoceptor (β2-AR). Immunoblots are from representative 
experiments. β2-AR levels assessed in the left ventricle are expressed in arbitrary units (a.u.). † p< 
0.05 vs Vehicle; ‡ p< 0.01 vs Vehicle. 
Fig 5. Phosphorylated/total ratio of kinases (Akt and GSK-3β) in baseline conditions. Blots 
are from representative experiments and ratios are assessed from kinase form levels detected in 
the left ventricle. † p< 0.05 vs Vehicle; # p< 0.01 vs Short_ND. 
 
Fig 6. Phosphorylated/total ratio of kinases (Akt and GSK-3β) in reperfusion. Blots are from 
representative experiments and ratios are assessed from kinase form levels detected in the left 
ventricle. I/R, Ischemia/Reperfusion; PostC, Postconditioning. 
* p< 0.05 vs I/R; † p< 0.05 vs Vehicle; # p< 0.05 vs Short_ND. 
 
Fig 7. Expression of phosphatases (PP2A sub A and PP2A sub B) in baseline conditions. 
Blots are from representative experiments. Phosphatases levels assessed in the left ventricle are 
expressed in arbitrary units (a.u.). † p< 0.05 vs Vehicle; # p< 0.01 vs Short_ND. 
 
Fig 8. Expression of phosphatases (PP2A sub A and PP2A sub B) in reperfusion. Blots are 
from representative experiments. Phosphatases levels assessed in the left ventricle are expressed 
in arbitrary units (a.u.). I/R, Ischemia/Reperfusion; PostC, Postconditioning. 
* p< 0.05 vs I/R; † p< 0.05 vs Vehicle; # p< 0.01 vs Short_ND. 
 
 
  
 
 
 
 
 
  
